Convergent pathobiologic model of Parkinson's disease

Annals of the New York Academy of Sciences

Volumn 991, Issue , 2003, Pages 152-166

  Maguire Zeiss, Kathleen A ^a   Federoff, Howard J ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Parkinson's disease; Single chain antibodies; Synuclein; Transgenic animals

Indexed keywords

SYNUCLEIN; TOXIC SUBSTANCE;

ANIMAL MODEL; CELL DEATH; CONFERENCE PAPER; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; LEWY BODY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROMOTER REGION; PROTEIN AGGREGATION; RAT; TRANSGENIC ANIMAL;

ANIMALIA;

EID: 0037713491     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2003.tb07473.x     Document Type: Conference Paper

References (83)

1. BEAL, M.F. 2001. Experimental models of Parkinson's disease. Nat. Rev. Neurosci. 2: 325-334.
2. BETARBET, R., et al. 2000. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3: 1301-1306.
3. BETARBET, R., et al. 2002. Animal models of Parkinson's disease. Bioessays 24: 308-318.
4. BOWERS, W.J., et al. 1997. Gene therapeutic strategies for neuroprotection: implications for Parkinson's disease. Exp Neurol. 144: 58-68.
5. BOWERS, W.J., et al. 2001. Gene therapeutic approaches to the treatment of Parkinson's disease. Clin. Neurosci. Res. 1: 483-495.
6. BROOKS, A.I., et al. 1999. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res. 823: 1-10.
7. DAWSON, T., et al. 2002. Animal models of PD: pieces of the same puzzle? Neuron 35: 219-222.
8. KOWALL, N.W., et al. 2000. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 11: 211-213.
9. MANNING-BOG, A.B., et al. 2002. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem. 277: 1641-1644.
10. MIZUNO, Y., et al. 1999. Genetic and environmental factors in the pathogenesis of Parkinson's disease. Adv. Neurol. 80: 171-179.
11. OLANOW, C.W. & W.G. TATTON. 1999. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22: 123-144.
12. SCHMIDT, N. & B. FERGER. 2001. Neurochemical findings in the MPTP model of Parkinson's disease. J. Neural Transm. 108: 1263-1282.
13. SCHWARTING, R.K. & J.P. HUSTON. 1996. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 50: 275-331.
14. THIRUCHELVAM, M., et al. 2000. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease? Brain Res. 873: 225-234.
15. THIRUCHELVAM, M., et al. 2000. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J. Neurosci. 20: 9207-9214.
16. THIRUCHELVAM, M., et al. 2002. Developmental exposure to the pesticides paraquat and maneb and the Parkinson's disease phenotype. Neurotoxicology 23: 621-633.
17. VILA, M., et al. 2000. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 74: 721-729.
18. STEECE-COLLIER, K., et al. 2002. Etiology of Parkinson's disease: genetics and environment revisited. Proc. Natl. Acad. Sci. USA 99: 13972-13974.
19. PARKINSON, J. 1817. An Essay on the Shaking Palsy. Sherwood, Neely, and Jones. London.
20. KITADA, T., et al. 1998. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392: 605-608.
21. KRUGER, R., et al. 1998. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18: 106-108.
22. POLYMEROPOULOS, M.H., et al. 1996. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 274: 1197-1199.
23. POLYMEROPOULOS, M.H., et al. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
24. POLYMEROPOULOS, M.H. 2000. Genetics of Parkinson's disease. Ann. N.Y. Acad. Sci. 920: 28-32.
25. SVEINBJORNSDOTTIR, S., et al. 2000. Familial aggregation of Parkinson's disease in Iceland. N. Engl. J. Med. 343: 1765-1770.
26. GORELL, J.M., et al. 1998. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50: 1346-1350.
27. SEIDLER, A., et al. 1996. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 46: 1275-1284.
28. CADET, J.L. 2001. Molecular neurotoxicological models of Parkinsonism: focus on genetic manipulation of mice. Parkinsonism Relat. Disord. 8: 85-90.
29. MORRISH, P.K., et al. 1995. Clinical and [18F] dopa PET findings in early Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 59: 597-600.
30. PATE, B.D., et al. 1993. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann. Neurol. 34: 331-338.
31. SANCHEZ-PERNAUTE, R., et al. 2002. Functional imaging of the dopamine system: in vivo evaluation of dopamine deficiency and restoration. Neurotoxicology 23: 469-478.
32. MAREK, K., et al. 2001. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 57: 2089-2094.
33. CENTONZE, D., et al. 1999. Neurophysiology of Parkinson's disease: from basic research to clinical correlates. Clin. Neurophysiol. 110: 2006-2013.
34. MEZEY, E., et al. 1998. Alpha synuclein is present in Lewy bodies in sporadic Parkinson's disease. Mol. Psych. 3: 493-499.
35. SPILLANTINI, M.G., et al. 1997. Alpha-synuclein in Lewy bodies. Nature 388: 839-840.
36. SPILLANTINI, M.G., et al. 1998. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA 95: 6469-6473.
37. TROJANOWSKI, J.Q. & V.M. LEE. 1998. Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch. Neurol. 55: 151-152.
38. WAKABAYASHI, K., et al. 1998. Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol. (Berl.) 96: 445-452.
39. WAKABAYASHI, K., et al. 1998. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci. Lett. 249: 180-182.
40. LANGSTON, J.W., et al. 1983. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979-980.
41. LANGSTON, J.W., et al. 1999. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46: 598-605.
42. ABBAS, N., et al. 1999. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Hum. Mol. Genet. 8: 567-574.
43. HARHANGI, B.S., et al. 1999. The Ile93Met mutation in the ubiquitin carboxy-terminal-hydrolase-L1 gene is not observed in European cases with familial Parkinson's disease. Neurosci. Lett. 270: 1-4.
44. HILKER, R., et al. 2001. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann. Neurol. 49: 367-376.
45. ISHIKAWA, A. & S. TSUJI. 1996. Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism. Neurology 47: 160-166.
46. LEROY, E., et al. 1998. Deletions in the Parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson's disease. Hum. Genet. 103: 424-427.
47. LUCKING, C.B., et al. 2000. Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N. Engl. J. Med. 2000. 342: 1560-1567.
48. RIESS, O. & R. KRUGER. 1999. Parkinson's disease - a multifactorial neurodegenerative disorder. J. Neural. Transm. Suppl. 56: 113-125.
49. TANAKA, Y., et al. 2001. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10: 919-926.
50. VALENTE, E.M., et al. 2001. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am. J. Hum. Genet. 68: 895-900.
51. VAN DE WARRENBURG, B.P., et al. 2001. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 56: 555-557.
52. ZHANG, Y., et al. 2000. Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol. Dis. 7: 240-250.
53. DONG, Z., et al. 2002. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP. J. Neurobiol. 53: 1-10.
54. GOMEZ-SANTOS, C., et al. 2002. MPP+ increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells. Brain Res. 935: 32-39.
55. RATHKE-HARTLIEB, S., et al. 2001. Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice. J. Neurochem. 77: 1181-1184.
56. KAHLE, P.J., et al. 2000. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci. 20: 6365-6373.
57. LEE, M.K., et al. 2002. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala- 53→Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. USA 99: 8968-8973.
58. MASLIAH, E., et al. 2000. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287: 1265-1269.
59. VAN DER PUTTEN, H., et al. 2000. Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20: 6021-6029.
60. MATSUOKA, Y., et al. 2001. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 8: 535-539.
61. RICHFIELD, E.K., et al. 2002. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp. Neurol. 175: 35-48.
62. CLAYTON, D.F. & J.M. GEORGE. 1998. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration, and disease. Trends Neurosci. 21: 249-254.
63. HSU, L.J., et al. 1998. Expression pattern of synucleins (non-Abeta component of Alzheimer's disease amyloid precursor protein/alpha-synuclein) during murine brain development. J. Neurochem. 71: 338-344.
64. TAKENOUCHI, T., et al. 2001. Reduced neuritic outgrowth and cell adhesion in neuronal cells transfected with human alpha-synuclein. Mol. Cell. Neurosci. 17: 141-150.
65. GEORGE, J.M., et al. 1995. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15: 361-372.
66. PRZEDBORSKI, S., et al. 1996. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc. Natl. Acad. Sci. USA 93: 4565-4571.
67. LEE, F.J., et al. 2001. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 15: 916-926.
68. TABRIZI, S.J., et al. 2000. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum. Mol. Genet. 9: 2683-2689.
69. LAI, C.T. & P.H. YU. 1997. Dopamine- and L-beta-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors. Biochem. Pharmacol. 53: 363-372.
70. SULZER, D. 2001. Alpha-synuclein and cytosolic dopamine: stabilizing a bad situation. Nat. Med. 7: 1280-1282.
71. LAVOIE, M.J. & T.G. HASTINGS. 1999. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J. Neurosci. 19: 1484-1491.
72. HASTINGS, T.G., et al. 1996. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. USA 93: 1956-1961.
73. CONWAY, K.A., et al. 2001. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294: 1346-1349.
74. RABINOVIC, A.D., et al. 2000. Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine. Neuroscience 101: 67-76.
75. HASHIMOTO, M., et al. 1999. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 10: 717-721.
76. MANN, D.M., et al. 1990. The prevalence of amyloid (A4) protein deposits within the cerebral and cerebellar cortex in Down's syndrome and Alzheimer's disease. Acta Neuropathol. (Berl.) 80: 318-327.
77. OGOMORI, K., et al. 1989. Beta-protein amyloid is widely distributed in the central nervous system of patients with Alzheimer's disease. Am. J. Pathol. 134: 243-251.
78. SUENAGA, T., et al. 1990. Modified Bielschowsky and immunocytochemical studies on cerebellar plaques in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 1990. 49: 31-40.
79. FORLONI, G., et al. 1995. Protein misfolding in Alzheimer's and Parkinson's disease: genetics and molecular mechanisms. Neurobiol. Aging 23: 957.
80. MALONE, J. & M.A. SULLIVAN. 1996. Analysis of antibody selection by phage display utilizing anti-phenobarbital antibodies. J. Mol. Recognit. 9: 738-745.
81. ZHU, Q., et al. 1999. Extended half-life and elevated steady-state level of a single-chain Fv intrabody are critical for specific intracellular retargeting of its antigen, caspase-7. J. Immunol. Methods 231: 207-222.
82. LECERF, J.M., et al. 2001. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc. Natl. Acad. Sci. USA 98: 4764-4769.
83. O'FARRELL, P.H. 1975. High resolution two-dimensional electrophoresis of proteins. J. Biol. Chem. 250: 4007-4021.